Grant: Master's Award: Canada Graduate Scholarships
McGill University
$27,000.00
Lipid nanoparticles delivering CTNS mRNA to kidneys could pave the way to novel cystinosis treatments
FY 2024-25
Summary
Cystinosis is an ultra-rare recessive disorder in which cystine transport across the lysosomal membrane is impeded. This occurs due to biallelic loss-of-function mutations in the CTNS gene, which encodes two isoforms of the Cystinosin protein. The major isoform exports cystine into the cytoplasm by forming cystine-specific channels across the lysosomal membrane. However, the minor Cystinosin isoform is found at the apical surface and in various subcellular vesicles, including autophagosomes. Thus, loss of Cystinosin causes intralysosomal cystine accumulation and disturbance of autophagocytosis in all cells. When started early in life, oral cysteamine can cleave the internal disulfide of cystine, generating a smaller sulfide that can exit the lysosome through an alternative channel. Although intralysosomal cystine is reduced by 80-90%, and organ deterioration is slowed, all patients eventually need kidney transplantation and die prematurely. This suggests that Cystinosin is required for cell functions beyond its role as a lysosomal cystine channel.
This project is a collaboration with Moderna, to show that the mRNA/lipid nanoparticle (LNP) therapy use to generate a COVID vaccine can be repurposed as a therapy for cystinosis. We will first test the hypothesis that CTNSGYDQL (major) isoform is required to reduce intracellular cystine levels, while CTNSLKG (minor) isoform is needed to restore autophagocytosis. Secondly, we will identify the optimal mRNA/LNP to deliver stabilized-CTNS to mouse kidney and other non-hepatic tissues. We will verify that dual therapy with both CTNS isoforms normalizes cystine and restores regular autophagosome function.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
530147
Name
Bejan Catargiu Luca
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Lipid nanoparticles delivering CTNS mRNA to kidneys could pave the way to novel cystinosis treatments
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autophagy; Cell Biology; Child Health; Cystinosis; Genetics; Inherited Diseases; Lipid Nanoparticles; Mrna Therapy; Nephrology; Vaccine
Abstract
Cystinosis is an ultra-rare recessive disorder in which cystine transport across the lysosomal membrane is impeded. This occurs due to biallelic loss-of-function mutations in the CTNS gene, which encodes two isoforms of the Cystinosin protein. The major isoform exports cystine into the cytoplasm by forming cystine-specific channels across the lysosomal membrane. However, the minor Cystinosin isoform is found at the apical surface and in various subcellular vesicles, including autophagosomes. Thus, loss of Cystinosin causes intralysosomal cystine accumulation and disturbance of autophagocytosis in all cells. When started early in life, oral cysteamine can cleave the internal disulfide of cystine, generating a smaller sulfide that can exit the lysosome through an alternative channel. Although intralysosomal cystine is reduced by 80-90%, and organ deterioration is slowed, all patients eventually need kidney transplantation and die prematurely. This suggests that Cystinosin is required for cell functions beyond its role as a lysosomal cystine channel.
This project is a collaboration with Moderna, to show that the mRNA/lipid nanoparticle (LNP) therapy use to generate a COVID vaccine can be repurposed as a therapy for cystinosis. We will first test the hypothesis that CTNSGYDQL (major) isoform is required to reduce intracellular cystine levels, while CTNSLKG (minor) isoform is needed to restore autophagocytosis. Secondly, we will identify the optimal mRNA/LNP to deliver stabilized-CTNS to mouse kidney and other non-hepatic tissues. We will verify that dual therapy with both CTNS isoforms normalizes cystine and restores regular autophagosome function.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bejan Catargiu, Luca
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~